Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer.
Curr Oncol
; 31(3): 1162-1169, 2024 02 22.
Article
em En
| MEDLINE
| ID: mdl-38534919
ABSTRACT
(1) Background:
Somatic and germline alterations can be commonly found in prostate cancer (PCa) patients. The aim of our present study was to perform a comprehensive review of the current literature in order to examine the impact of BRCA mutations in the context of PCa as well as their significance as genetic biomarkers. (2)Methods:
A narrative review of all the available literature was performed. Only "landmark" publications were included. (3)Results:
Overall, the number of PCa patients who harbor a BRCA2 mutation range between 1.2% and 3.2%. However, BRCA2 and BRCA1 mutations are responsible for most cases of hereditary PCa, increasing the risk by 3-8.6 times and up to 4 times, respectively. These mutations are correlated with aggressive disease and poor prognosis. Gene testing should be offered to patients with metastatic PCa, those with 2-3 first-degree relatives with PCa, or those aged < 55 and with one close relative with breast (age ≤ 50 years) or invasive ovarian cancer. (4)Conclusions:
The individualized assessment of BRCA mutations is an important tool for the risk stratification of PCa patients. It is also a population screening tool which can guide our risk assessment strategies and achieve better results for our patients and their families.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Detecção Precoce de Câncer
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article